They have announced a partnership with RHHBY to jointly develop allo CAR-T therapies. Per the terms, the Swiss pharma giant will receive either exclusive rights or options from Poseida to develop and sell multiple CARs globally against targets in multiple myeloma, B-cell lymphomas, and other hematologic malignancies. In return, Poseida will receive $110M of upfront payment in addition to $110M in near-term milestones and other payments within the next several years. Notably, the company is entitled to receive up to $6B worth of milestones and other payments based on research, development, launch, and net sales. The completion of the agreement is subject to clearance under the HSR Act.
Market Data 
Markets 
AI
